Safety And Efficacy Of Combination Lurbinectedin Plus Doxorubicin From A Phase 1b Trial In Patients With Advanced/Metastatic Soft Tissue Sarcoma.

Gregory M Cote Candace L Haddox Edwin Choy Priscilla A Merriam Emanuele Mazzola Vinayak Venkataraman Thierry Alcindor Andrew J Wagner George D Demetri Suzanne George

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

In this phase 1b study, the recommended dose is lurbinectedin 3.2 mg/m2 in combination with doxorubicin 25 mg/m2 every 3 weeks. The study combination was well-tolerated and demonstrated intriguing clinical activity.

Keyphrases

drug delivery
squamous cell carcinoma
clinical trial
randomized controlled trial
cancer therapy
open label
phase ii